Stem Cell Therapy for Retinal Degeneration: The Evidence to Date

Area of Science:

• Ophthalmology
• Regenerative Medicine
• Cell Biology

Background:

• Retinal diseases cause vision loss, and current treatments are insufficient for retinal repair.
• Stem cell therapy is being investigated as a novel approach for retinal regeneration.
• Various retinal conditions, including AMD, DR, RP, and Stargardt's disease, are targets for stem cell treatments.

Purpose of the Study:

• To review preclinical and clinical evidence of stem cell therapy for retinal degeneration.
• To summarize the effectiveness and safety of different stem cell types in treating retinal diseases.
• To identify current limitations in the clinical application of stem cells for retinal repair.

Main Methods:

• Review of preclinical studies in animal models.
• Analysis of human clinical trials involving stem cell transplantation.
• Examination of stem cell-derived retinal pigment epithelial (RPE) cells, embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and mesenchymal stem cells (MSCs).

Main Results:

• Transplantation of ESCs and iPSCs-derived RPE cells shows promising results in preclinical models and clinical studies with no severe side effects.
• Mesenchymal stem cells (MSCs) have demonstrated positive clinical outcomes in treating optic neuropathy, RP, DR, and glaucoma.
• Stem cell therapies have the potential to improve visual acuity and retinal function in various degenerative conditions.

Conclusions:

• Stem cell therapy offers a promising avenue for treating retinal degeneration and vision loss.
• ESC and iPSC-derived RPE cells, as well as MSCs, are key players in current stem cell research for retinal diseases.
• Further research is needed to address existing limitations and optimize stem cell utilization for widespread clinical application in ophthalmology.